Applied DNA Sciences to Present at Rodman & Renshaw Annual Global Investment Conference on September 10, 2014

Dr. James A. Hayward, CEO and President of Applied DNA Sciences, is scheduled to speak at the Rodman & Renshaw Annual Global Investment Conference at the New York Palace Hotel, New York, NY on September 10, 2014 at 1:15 pm.

        Print
| Source: Applied DNA Sciences

STONY BROOK, N.Y., Aug. 27, 2014 (GLOBE NEWSWIRE) -- via PRWEB - August 26, 2014. Applied DNA Sciences, Inc. (OTCQB:APDN), a biotechnology firm that provides DNA-based authentication and security solutions and services, announced today that Dr. James A. Hayward, CEO and President, is scheduled to speak at the Rodman & Renshaw Annual Global Investment Conference at the New York Palace Hotel, New York, NY on September 10, 2014 at 1:15 pm EDT. Dr. Hayward intends to provide an update on the company's business activities including its development of botanical-DNA based security and authentication solutions and services.

Applied DNA Sciences' presentation will be in the Adams Salon, 4th Floor.

A live webcast of the presentation will be available at the following website address:

http://wsw.com/webcast/rrshq24/apdn/

Viewers are urged to register at this address sometime in advance.

A replay of the webcast will be available at the same address, and also on the company's website Investor Information page:

http://www.adnas.com/investor-information-0

About Applied DNA Sciences

APDN is a provider of botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the uncopyable marker that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of products such as DNAnet®, our anti-theft product, SigNature® T, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.

The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K filed on December 20, 2013 (amended on May 1, 2014) and our subsequent quarterly reports on Form 10-Q/A (for the quarterly period ended December 31, 2013) and Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

media contact Mitchell Miller, 631-240-8818
investor contact Debbie Bailey, 631-240-8817
web http://www.adnas.com
twitter @APDN, @APDNInvestor

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/08/prweb12120500.htm

Applied DNA Sciences
Mitchell Miller

+1 (631) 240-8818